Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche has signed a licensing agreement with Nycomed, under which Roche will transfer Bonviva marketing authorization approvals for certain Asia-Pacific markets to Nycomed.
Subscribe to our email newsletter
The tie up allows Nycomed to become the sole marketing authorization holder in all the licensed territories.
Bonviva is a bisphosphonate used in the treatment of osteoporosis in postmenopausal women.
Under the agreement, Nycomed gets Bonviva marketing authorization approval for China, Hong Kong, Malaysia, Australia, New Zealand, Philippines, Singapore, Taiwan and Vietnam and a future option to commercialize Bonviva in additional Asia-Pacific territories.
Further financial terms of the agreement are been disclosed.
Roche Commercial Operations executive vice president Guido Oelkers said the in-licensing of Bonviva from Roche is another important step towards Nycomed’s expansion in the Asia-Pacific region and demonstrates their growing attraction as a marketing partner for companies and brands in these countries.
"Bonviva is a high quality product which plays an important role in combating the impact of osteoporosis in post menopausal women," Oelkers said.